Absci Corporation (ABSI)
After hours:
| Previous close | 4.98 |
| Open | 5.22 |
| Bid | 5.07 x 400 |
| Ask | 5.10 x 400 |
| Day's range | 5.05 - 5.44 |
| 52-week range | 1.11 - 6.72 |
| Volume | |
| Avg. volume | 1,480,750 |
| Market cap | 574.462M |
| Beta (5Y monthly) | 2.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.20 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.60 |
ZacksCytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GlobeNewswireAbsci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating resul
ZacksAbsci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
